A Community Team (ACT): Redefining Research, or ACT, is planning project that created new collaboration models to enhance engagement between industry, researchers, & a global pool of patients early in the drug discovery environment. ACT was one of three winners, and the only immunology winner, in Celgene’s 2015 Innovation Impact Awards.
The main objective of ACT is to develop a platform to advance existing engagement methods between patients, industry, and researchers in order to improve outcomes and better utilize research dollars in a patient population where disease experiences can vary per individual. This initial planning project focused strongly on early drug development and treatment intervention, but future work will also include pre-clinical trial through post-market surveillance phases of the R & D continuum. A second objective is to ensure all patients have the opportunity to engage in various research initiatives with different stakeholder groups, regardless of geographic location, disease limitations, or former advocacy experience.
The end goal for the ACT is to establish a robust, patient-led platform where industry, researchers, and a realistic sample of patients can collaborate in all phases of the Research and Development (R & D) continuum so that outcomes can be improved and research dollars better utilized. Various methods of engagement will produce statistically relevant data which can be used to further research and influence public policy and will encourage patients not usually “at the table” to participate.
Celgene Corporation was not involved in any way regarding ideas, design, or management of the ACT project and was not the only pharmaceutical company invited to participate in discussions conducted to better understand current engagement barriers.
ACT II expansion will include:
Copyright 2017. All rights reserved. Information on this site is intended for informational purposes only Our foundation does not engage in the practice of medicine. Please consult a physician to obtain personal healthcare and treatment options. Tax ID: 27-1214308